Zenas BioPharma, Financials
| ZBIO Etf | USD 9.16 0.34 3.58% |
Zenas |
The data published in Zenas BioPharma,'s official financial statements typically reflect Zenas BioPharma,'s business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving Zenas BioPharma,'s quantitative information. For example, before you start analyzing numbers published by Zenas accountants, it's essential to understand Zenas BioPharma,'s liquidity, profitability, and earnings quality within the context of the Biotechnology space in which it operates.
Zenas BioPharma, Etf Summary
Zenas BioPharma, competes with Dogwood Therapeutics,, Elevation Oncology, Elicio Therapeutics, Enliven Therapeutics, and EnGene Holdings. The investment seeks daily investment results, before fees and expenses, that correspond to three times the inverse of the daily performance of the NASDAQ Biotechnology Index. ProShares UltraPro is traded on NGM Exchange in the United States.Specialization | Healthcare, Biotechnology |
| Instrument | USA Etf View All |
| Exchange | NASDAQ Exchange |
| CUSIP | 98937L105 |
| Region | Others |
| Investment Issuer | Others |
| Location | Massachusetts; U.S.A |
| Business Address | North Building, Waltham, |
| Etf Family | Biotechnology |
| Fund Category | Others |
| Portfolio Concentration | Others |
| Benchmark | Dow Jones Industrial |
| Website | zenasbio.com |
| Phone | 857 271 2954 |
| Currency | USD - US Dollar |
Zenas BioPharma, Key Financial Ratios
| Beta | -2.35 | ||||
| Last Dividend Paid | 0.002 |
Zenas Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Zenas BioPharma,'s current stock value. Our valuation model uses many indicators to compare Zenas BioPharma, value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Zenas BioPharma, competition to find correlations between indicators driving Zenas BioPharma,'s intrinsic value. More Info.Zenas BioPharma, Common is rated below average in beta as compared to similar ETFs. It is rated below average in one year return as compared to similar ETFs . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Zenas BioPharma,'s earnings, one of the primary drivers of an investment's value.Zenas BioPharma, Common Systematic Risk
Zenas BioPharma,'s systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Zenas BioPharma, volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was fourteen with a total number of output elements of fourty-seven. The Beta measures systematic risk based on how returns on Zenas BioPharma, Common correlated with the market. If Beta is less than 0 Zenas BioPharma, generally moves in the opposite direction as compared to the market. If Zenas BioPharma, Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Zenas BioPharma, Common is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Zenas BioPharma, is generally in the same direction as the market. If Beta > 1 Zenas BioPharma, moves generally in the same direction as, but more than the movement of the benchmark.
Zenas BioPharma, December 12, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Zenas BioPharma, help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Zenas BioPharma, Common. We use our internally-developed statistical techniques to arrive at the intrinsic value of Zenas BioPharma, Common based on widely used predictive technical indicators. In general, we focus on analyzing Zenas Etf price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Zenas BioPharma,'s daily price indicators and compare them against related drivers.
| Information Ratio | (0.17) | |||
| Maximum Drawdown | 26.69 | |||
| Value At Risk | (11.81) | |||
| Potential Upside | 8.86 |
Other Information on Investing in Zenas Etf
Zenas BioPharma, financial ratios help investors to determine whether Zenas Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Zenas with respect to the benefits of owning Zenas BioPharma, security.